Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNV-SERPINE1 inhibitor
- Development stage
- Preclinical
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LNV-SERPINE1 inhibitor is an experimental therapeutic platform consisting of engineered cell membrane nanovesicles (LNVs) loaded with inhibitors of SERPINE1 (Plasminogen Activator Inhibitor-1). This drug is specifically designed to address temozolomide (TMZ) resistance in glioblastoma multiforme (GBM). The nanovesicles are engineered to cross the blood-brain barrier (BBB) and deliver their payload directly to the tumor microenvironment. By inhibiting SERPINE1, the treatment suppresses GBM cell viability, migration, and invasion, while also downregulating Vascular Endothelial Growth Factor (VEGF) expression to inhibit angiogenesis and tumor progression. This approach aims to overcome the aggressive nature and chemoresistance of GBM through targeted delivery and modulation of pivotal resistance-associated genes.
- Other names
- SERPINE1-targeted nanovesiclesSERPINE-1-targeted nanovesiclesSERPINE 1-targeted nanovesiclesEngineered nanovesicles targeting SERPINE1
02
Targets
PAI-1 (Plasminogen activator inhibitor type 1)
Beyond the preview
Go deeper on LNV-SERPINE1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNV-SERPINE1 inhibitor.